• DVM360_Conference_Charlotte,NC_banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Conference Coverage
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Listing
Conference Proceedings
Resources
CBD in Pets
CE Requirements by State
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Hot Literature: Spironolactone: A promising adjunctive therapy for myxomatous mitral valve disease

June 1, 2010
Avi Blake, DVM

Spironolactone, a selective aldosterone inhibitor, has been shown to decrease mortality in people with congestive heart failure.

Human medicine has once again presented veterinarians with a possibility for improving the quality of life and survival times of many canine patients. Spironolactone, a selective aldosterone inhibitor, has been shown to decrease mortality in people with congestive heart failure. As heart failure progresses, aldosterone increases with the stimulation of several neurohormonal systems. These systems act to compensate for decreasing cardiac function. Aldosterone, however, increases extracellular fluid volume, putting increased strain on the heart. Additionally, it has a direct negative affect on the cardiac muscle and vasculature. In people, this long-term exposure to high aldosterone concentrations results in fibrosis-not a good thing in cases of cardiac disease.

Conventional treatments for heart failure include angiotensin-converting enzyme (ACE) inhibitors and furosemide. ACE inhibitors are poor suppressors of aldosterone secretion in both people and dogs. Furthermore, furosemide increases the aldosterone secretion. It was for these reasons that researchers in Europe conducted a double-blinded field study in dogs with naturally occurring myxomatous mitral valve disease (MMVD) to test the possible benefits of adding spironolactone therapy to conventional treatments.

More than 200 dogs were enrolled in the study, which consisted of two phases: a short-term evaluation including a two- and a three-month study, and a long-term evaluation (12-month study) that included dogs that had completed one of the short-term studies. At presentation, all of the dogs had moderate to severe mitral regurgitation caused by MMVD with an International Small Animal Cardiac Health Council classification of II or III. To participate, the dogs also had to be exhibiting a minimum of three clinical signs, including coughing, dyspnea, or syncope, and at least one behavioral sign such as decreased activity, decreased mobility, or altered demeanor.

The dogs were treated with conventional therapies, including an ACE inhibitor and furosemide. Treatment with digoxin or L-carnitine was also allowed. Veterinarians were permitted to adjust dosages as needed throughout the study. In addition to this therapy, spironolactone (2 mg/kg orally once a day) or placebo was added. Complete clinical evaluations were then performed on the dogs during the first week and at days 28, 56, and 84. For the long-term study, evaluations were continued at three-month intervals.

Results of the study were encouraging. For dogs treated with spironolactone, the 18-month survival rate was 84% compared with 66% in the control group. A primary endpoint (cardiac-related death, euthanasia, or severe worsening of mitral regurgitation) was reached in only 10.8% of patients receiving spironolactone compared with 25.5% of those given placebo. The results were even more exciting when considering only cardiac-related mortality, where there was a 69% reduction in the risk when an animal was treated with spironolactone.

Advertisement

This study was published in the Journal of Veterinary Internal Medicine earlier this year, and while it does not provide all of the answers to improving the quality and quantity of life for canine cardiac patients, it does offer some exciting new data to potentially improve the treatment of mitral regurgitation caused by MMVD.

Bernay F, Bland JM, Häggström J, et al. Efficacy of spironolactone on survival in dogs with naturally occurring mitral regurgitation caused by myxomatous mitral valve disease. J Vet Intern Med 2010;24(2):331-341.

Abstract available at http://www3.interscience.wiley.com/journal/123262185/abstract

Related Content:

Cardiology
Does feline hypertension raise your blood pressure?
Does feline hypertension raise your blood pressure?
Tips for pet heart health
Tips for pet heart health
Tips for accurate blood pressure measurement
Tips for accurate blood pressure measurement

Advertisement

Latest News

News wrap-up: This week’s headlines, plus dvm360® launches its first CE podcast

Educating clients on brachycephalic breeds

Viticus group seeks applications for veterinary boot camp scholarship

Unusual parasite strain kills 4 California sea otters

View More Latest News
Advertisement